Top

Published in:

01-06-2023 | Dysphagia | Case report

Budesonide/pembrolizumab/proton pump inhibitor

Severe Dysphasia, eosinophilic oesophagitis, autoimmune gastritis and lack of efficacy: case report

Author Information

An event is serious (based on the ICH definition) when the patient outcome is&colon;

…

Yu KK, et al. Severe Dysphasia With Eosinophilic Esophagitis Pattern of Injury and Autoimmune Gastritis Related to Pembrolizumab Therapy. American Journal of Gastroenterology 117 (Suppl. 2): S1589-S1590, No. 10, Oct 2022. Available from: URL: http://doi.org/10.14309/01.ajg.0000866128.21433.2b [abstract]

Title: Budesonide/pembrolizumab/proton pump inhibitor
Severe Dysphasia, eosinophilic oesophagitis, autoimmune gastritis and lack of efficacy: case report
Publication date: 01-06-2023
Publisher: Springer International Publishing
Keywords: Dysphagia
Dysphagia
Esophagitis
Gastritis
Proton Pump Inhibitors
Budesonide
NSCLC
NSCLC
Ramucirumab
Dysphagia
Published in: Reactions Weekly / Issue 1/2023
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-023-40324-1